Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations

The non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations can be therapeutically treated by EGFR-TKI such as erlotinib and gefitinib. However, about 40% of individuals harboring EGFR-TKI sensitive mutations are still resistant to EGFR-TKI. And, it has been reported that both PTEN...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Choi, Junyoung, Yoon, Shinkyo, Kim, Deokhoon, Moon, Yong Wha, Lee, Chang Hoon, Seo, Seyoung, Cheon, Jaekyung, Gho, Yong Song, Kim, Changhoon, Lee, Eung Ryoung, Kim, Soo-Youl, Lee, Kyoungmin, Ha, Joo Young, Park, Sook Ryun, Kim, Sang-We, Park, Kang-Seo, Lee, Dae Ho
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726998/
https://ncbi.nlm.nih.gov/pubmed/31497352
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi